SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharmaceuticals informs about trading window closure

23 Mar 2022 Evaluate
Jenburkt Pharmaceuticals has informed that the trading window for all the trades in the equity shares of the Company by any of the designated persons and insiders of the Company, including their immediate relative(s), shall remain closed from 1st April, 2022 till 48 hours after the price sensitive information viz. audited financial results, pertaining to the quarter and financial year ended on 31st March, 2022 are disseminated or made public. The Company shall intimate the exchange separately about the schedule of Board Meeting for considering the said unaudited financial results, in due course.

The above information is a part of company’s filings submitted to BSE.

Jenburkt Pharma Share Price

1025.60 6.35 (0.62%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×